Medication-related osteonecrosis of the jaws (MRONJ) in cancer patients treated with denosumab VS. zoledronic acid : a systematic review and meta-analysis
NAGIOS: RODERIC FUNCIONANDO

Medication-related osteonecrosis of the jaws (MRONJ) in cancer patients treated with denosumab VS. zoledronic acid : a systematic review and meta-analysis

DSpace Repository

Medication-related osteonecrosis of the jaws (MRONJ) in cancer patients treated with denosumab VS. zoledronic acid : a systematic review and meta-analysis

Show simple item record

dc.contributor.author Limones, Alvaro es
dc.contributor.author Sáez Alcaide, Luis Miguel es
dc.contributor.author Díaz-Parreño, Santiago Angulo es
dc.contributor.author Helm, Alexandra es
dc.contributor.author Bornstein, Michael M. es
dc.contributor.author Molinero Mourelle, Pedro es
dc.date.accessioned 2021-01-15T09:07:39Z
dc.date.available 2021-01-15T09:07:39Z
dc.date.issued 2020 es
dc.identifier.uri https://hdl.handle.net/10550/77133
dc.description.abstract The aim of the present study was to analyse the incidence, risk ratio (RR) and prognoses of two types of medication-related osteonecrosis of the jaws (MRONJ): denosumab-related osteonecrosis of the jaws (DRONJ) and Bisphosphonate-Related Osteonecrosis of the Jaws (BRONJ) in cancer patients under treatment with denosumab or zoledronic acid (ZA). An electronic and manual search was conducted for randomized controlled trials (RCTs) until May 2019. Assessment of the identified studies, risk of bias and data extraction were performed independently by two reviewers. The incidence of DRONJ and BRONJ and the RR to develop MRONJ were calculated at 1 year, 2 years and 3 years of exposure. It was also calculated the odds ratio (OR) of their respective prognoses. They were calculated normalizing the values of the individual studies to 1 year, 2 years or 3 years when necessary through robust regression models using a statistical program. From 1.277 references identified, 8 RCTs were included, which comprised a total of 13.857 patients with a variety of neoplasms. The incidence of DRONJ in cancer patients under treatment with denosumab ranged from 0.5 to 2.1% after 1 year, 1.1 to 3.0% after 2 years, and 1.3 to 3.2% after 3 years of exposure. The incidence of BRONJ in cancer patients under treatment with ZA ranged from 0.4 to 1.6% after 1 year of exposure, 0.8 to 2.1% after 2 years, and 1.0 to 2.3% after 3 years of exposure. Statistically significant differences were found between denosumab and ZA in the risk of developing MRONJ after 1, 2 and 3 years of exposure. Nevertheless, there were no significant differences in terms of patient prognosis. Denosumab is associated with a significantly higher risk of developing MRONJ compared to ZA. Nevertheless, no differences were found in its prognoses. es
dc.source Limones, Alvaro ; Sáez Alcaide, Luis Miguel ; Díaz-Parreño, Santiago Angulo ; Helm, Alexandra ; Bornstein, Michael M. ; Molinero Mourelle, Pedro. Medication-related osteonecrosis of the jaws (MRONJ) in cancer patients treated with denosumab VS. zoledronic acid : a systematic review and meta-analysis. En: Medicina oral, patología oral y cirugía bucal. Ed. inglesa, 25 3 2020: 10- es
dc.title Medication-related osteonecrosis of the jaws (MRONJ) in cancer patients treated with denosumab VS. zoledronic acid : a systematic review and meta-analysis es
dc.type info:eu-repo/semantics/article en
dc.type info:eu-repo/semantics/publishedVersion en
dc.subject.unesco UNESCO::CIENCIAS MÉDICAS es
dc.identifier.doi 10.4317/medoral.23324 es

View       (2.257Mb)

This item appears in the following Collection(s)

Show simple item record

Search DSpace

Advanced Search

Browse

Statistics